Abstract
Nineteen patients with different clinical subsets of cutaneous lupus erythematosus (LE) were treated with the aromatic retinoid etretinate. In 11 of them excellent or good treatment results were obtained within two to six weeks. Best response to etretinate therapy was seen in male patients with discoid lupus erythematosus. Etretinate should prove a valuable drug in LE therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
